NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that acceptance has been received by Capricor Therapeutics, Inc. (Headquarters: California, ...

NS Pharma, a subsidiary of Nippon Shinyaku Co., announced that acceptance has been received by Capricor Therapeutics (CAPR) from the U.S. FDA ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd ... an investigational cell therapy, as a treatment for patients diagnosed ...

The Nippon India Large Cap Fund - Growth has an AUM of 35667.30 crores & has delivered CAGR of 21.52% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.57%.

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into Or ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

Feb. 27, 2025 — Researchers are working to enhance battery safety and efficiency by developing solid-state alternatives to lithium-ion batteries. These batteries offer improved energy efficiency ...

Cell adhesion is the process by which cells form contacts with each other or with their substratum through specialized protein complexes. Intercellular adhesion can be mediated by adherens ...

1. Current NAV: The Current Net Asset Value of the Nippon India Small Cap Fund as of Mar 07, 2025 is Rs 146.33 for Growth option of its Regular plan. 2. Returns: Its trailing returns over different ...